Literature DB >> 23878160

On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention.

Gianluca Campo1, Rita Pavasini, Alberto Pollina, Matteo Tebaldi, Roberto Ferrari.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) show a poor prognosis after myocardial infarction (MI) and percutaneous coronary intervention (PCI). We evaluated on-treatment platelet reactivity (PR) and several gene polymorphisms related to PR in 130 patients undergoing PCI with and without COPD. Those with concomitant COPD showed higher on-treatment PR values both at the time of PCI and 1 month after. This finding may contribute to explain the poor prognosis of COPD patients after MI and PCI.

Entities:  

Keywords:  COPD epidemiology

Mesh：

Substances：

Year:  2013        PMID： 23878160     DOI： 10.1136/thoraxjnl-2013-203608

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  8 in total

Review 1.  Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Authors:  Mario Cazzola; Luigino Calzetta; Barbara Rinaldi; Clive Page; Giuseppe Rosano; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

2.  Ischemic heart disease among subjects with and without chronic obstructive pulmonary disease--ECG-findings in a population-based cohort study.

Authors:  Ulf Nilsson; Bengt Johansson; Berne Eriksson; Anders Blomberg; Bo Lundbäck; Anne Lindberg
Journal:  BMC Pulm Med       Date:  2015-12-04       Impact factor: 3.317

3.  Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2).

Authors:  Vijay Kunadian; Danny Chan; Hani Ali; Nina Wilkinson; Nicola Howe; Elaine McColl; Jared Thornton; Alexander von Wilamowitz-Moellendorff; Eva-Maria Holstein; Graham Burns; Andrew Fisher; Deborah Stocken; Anthony De Soyza
Journal:  BMJ Open       Date:  2018-05-26       Impact factor: 2.692

4.  Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.

Authors:  Gianluca Campo; Francesco Vieceli Dalla Sega; Rita Pavasini; Giorgio Aquila; Francesco Gallo; Francesca Fortini; Elisabetta Tonet; Paolo Cimaglia; Annamaria Del Franco; Gabriele Pestelli; Alessandro Pecoraro; Marco Contoli; Cristina Balla; Simone Biscaglia; Paola Rizzo; Roberto Ferrari
Journal:  Thromb Haemost       Date:  2017-03-23       Impact factor: 5.249

5.  Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial.

Authors:  Vijay Kunadian; Nina Wilson; Deborah D Stocken; Hani Ali; Elaine McColl; Graham Burns; Nicola Howe; Andrew Fisher; Anthony De Soyza
Journal:  ERJ Open Res       Date:  2019-08-05

Review 6.  Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease.

Authors:  Pere Almagro; Ramon Boixeda; Jesús Diez-Manglano; María Gómez-Antúnez; Francisco López-García; Jesús Recio
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-14

7.  Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study.

Authors:  Pere Almagro; Anna Lapuente; Julia Pareja; Sergi Yun; Maria Estela Garcia; Ferrán Padilla; Josep L I Heredia; Alex De la Sierra; Joan B Soriano
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-16

Review 8.  Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.

Authors:  Rita Pavasini; Guido Tavazzi; Simone Biscaglia; Federico Guerra; Alessandro Pecoraro; Fatima Zaraket; Francesco Gallo; Giosafat Spitaleri; Marco Contoli; Roberto Ferrari; Gianluca Campo
Journal:  Chron Respir Dis       Date:  2016-12-15       Impact factor: 2.444
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.